These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 2030316)
1. Persistent reduced solubilization of immune complexes in lepromatous leprosy patients with reactions. Ramanathan VD; Tyagi P; Ramanathan U; Katoch K; Sengupta U; Ramu G Int J Lepr Other Mycobact Dis; 1991 Mar; 59(1):5-11. PubMed ID: 2030316 [TBL] [Abstract][Full Text] [Related]
2. A sequential study of circulating immune complexes, complement and immunoglobulins in borderline tuberculoid leprosy patients with and without reactions. Ramanathan VD; Thyagi P; Ramanathan U; Katoch K; Ramu G Indian J Lepr; 1998; 70(2):153-60. PubMed ID: 9724850 [TBL] [Abstract][Full Text] [Related]
3. Solubilization of preformed immune complexes in sera of patients with type 1 and type 2 lepra reactions. Chakrabarty AK; Kashyap A; Sehgal VN; Saha K Int J Lepr Other Mycobact Dis; 1988 Dec; 56(4):559-65. PubMed ID: 3221112 [TBL] [Abstract][Full Text] [Related]
5. Activation of complement by circulating immune complexes isolated from leprosy patients. Tyagi P; Ramanathan VD; Girdhar BK; Katoch K; Bhatia AS; Sengupta U Int J Lepr Other Mycobact Dis; 1990 Mar; 58(1):31-8. PubMed ID: 2319186 [TBL] [Abstract][Full Text] [Related]
6. T lymphocyte subpopulations in leprosy patients and their relation with circulating immune complexes. Bottasso OA; Morini JC; Ramos G; Segal-Eiras A Allergol Immunopathol (Madr); 1990; 18(2):91-4. PubMed ID: 2142569 [TBL] [Abstract][Full Text] [Related]
7. Serum immune complexes in erythema nodosum leprosum reactions of leprosy. Rao TD; Rao PR Indian J Lepr; 1988 Apr; 60(2):189-95. PubMed ID: 3142953 [TBL] [Abstract][Full Text] [Related]
8. Immune complex modulation by plasma proteins. With special reference to the complement system and autoimmune diseases. Baatrup G Dan Med Bull; 1989 Oct; 36(5):443-63. PubMed ID: 2530063 [TBL] [Abstract][Full Text] [Related]
9. Epidemiologic characteristics of leprosy reactions. Scollard DM; Smith T; Bhoopat L; Theetranont C; Rangdaeng S; Morens DM Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):559-67. PubMed ID: 7868954 [TBL] [Abstract][Full Text] [Related]
10. Cutaneous delayed-type hypersensitivity responsiveness in lepromatous and borderline lepromatous leprosy patients as determined by MULTITEST CMI. Walsh DS; Villahermosa LG; Balagon MV; Abalos RM; Fajardo TT; Tan EV; Cellona RV; Walsh GP Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):518-26. PubMed ID: 10774662 [TBL] [Abstract][Full Text] [Related]
11. Immunologic defects in leprosy patients. I. Evidence of immune aberration of suppressor-T lymphocytes in lepromatous leprosy. Makonkawkeyoon S; Kasinrerk W; Dettrairat S; Vithayasai V Int J Lepr Other Mycobact Dis; 1990 Jun; 58(2):302-10. PubMed ID: 2142947 [TBL] [Abstract][Full Text] [Related]
12. Reduced complement-mediated immune complex solubilizing capacity and the presence of incompletely solubilized immune complexes in SLE sera. Baatrup G; Petersen I; Jensenius JC; Svehag SE Clin Exp Immunol; 1983 Nov; 54(2):439-47. PubMed ID: 6652967 [TBL] [Abstract][Full Text] [Related]
13. Incidence of late lepra reaction among multibacillary leprosy patients after MDT. Vijayakumaran P; Manimozhi N; Jesudasan K Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):18-22. PubMed ID: 7730714 [TBL] [Abstract][Full Text] [Related]
14. Humoral and cellular immune reactivity to recombinant M. leprae antigens in HLA-typed leprosy patients and healthy controls. Klatser PR; Janson AM; Thole JE; Buhrer S; Bos C; Soebono H; de Vries RR Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):178-89. PubMed ID: 9251589 [TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of immunotherapeutic efficacy of BCG and mw vaccines in patients of borderline lepromatous and lepromatous leprosy. Narang T; Kaur I; Kumar B; Radotra BD; Dogra S Int J Lepr Other Mycobact Dis; 2005 Jun; 73(2):105-14. PubMed ID: 16830653 [TBL] [Abstract][Full Text] [Related]
16. Significance of circulating immune complexes in pulmonary tuberculosis. Samuel AM; Ashtekar MD; Ganatra RD Clin Exp Immunol; 1984 Nov; 58(2):317-24. PubMed ID: 6437714 [TBL] [Abstract][Full Text] [Related]
17. Complement mediated solubilization: role of the complement in the clearance of circulating immune-complexes. Sánchez-Cuenca JM Allergol Immunopathol (Madr); 1994; 22(5):197-203. PubMed ID: 7840020 [TBL] [Abstract][Full Text] [Related]
18. Serologic response to mycobacterial proteins in hansen's patients during multidrug treatment. Rada E; Aranzazu N; Ulrich M; Convit J Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):414-21. PubMed ID: 10700916 [TBL] [Abstract][Full Text] [Related]
19. Circulating and tissue immune complexes in leprosy. Sehgal S; Kumar B Int J Lepr Other Mycobact Dis; 1981 Sep; 49(3):294-301. PubMed ID: 6976333 [TBL] [Abstract][Full Text] [Related]
20. Demonstration of apoptosis-associated cleavage products of DNA, complement activation products SC5b-9 and C3d/dg, and immune complexes CIC-C3d, CIC-IgA, and CIC-IgG in the urine of patients with membranous glomerulonephritis. Kotnik V; Premzl A; Skoberne M; Malovrh T; Kveder R; Kaplan-Pavlovcic S; Kotnik A; Stiblar-Martincic D Croat Med J; 2003 Dec; 44(6):707-11. PubMed ID: 14652883 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]